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Background. Streptococcus pneumoniae (SP) is a major cause of morbidity and mortality worldwide in all age
groups. Serious diseases often caused by pneumococci include pneumonia, meningitis and bacteremia.
Objective. The aim of this work was to estimate the hospitalization rate for SP in the Veneto region by
investigating pneumococcal-related discharges.
Material andmethods. This was a retrospective study based on hospital discharge data collected from 2008 to
2012 in the Veneto Region (north-east Italy). All hospitalizations for diseases potentially associatedwith SPwere
identiﬁed by searching the hospital discharge records, then the proportions of hospital admissions for pneumo-
nia, meningitis and septicemia attributable to the infection were calculated. Comorbidities were also graded
according to the Charlson Comorbidity Index (CCI). Data were analyzed using the chi square test and Student's
t-test for unpaired data, as appropriate. Signiﬁcant trends over the years considered were examined in terms
of average annual percent changes (AAPC). A p value b0.05 was considered signiﬁcant.
Results.We identiﬁed 62,946 hospital discharge records concerning diseases potentially associated with SP.
Among them, the proportion of SP-related hospital admissions (SP-HA) was estimated to be 23,089 (37.2%).
The estimated incidence of SP-HA was 94.0/100,000 population (102.8/100,000 in males and 85.6/100,000
in females; p b 0.01): 89.0 for pneumonia, 0.9 for meningitis, and 4.1 for septicemia. The incidence of SP-HA was
higher in children and the elderly, and the overall fatality rate was 11.0%. The overall economic burden of SP-HA
during the period considered was around €14.8 million a year, with an average cost of €3120 per hospitalization.
Conclusion. This study shows that hospitalization for SP-related disease has a considerable impact on the health
services, especially as far as children and the elderly are concerned.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Streptococcus pneumoniae (SP) is a major cause of morbidity and
mortality worldwide in all age groups. It can cause a number of diseases
of variable severity. After colonizing the nasopharyngeal mucosa, pneu-
mococci may spread contiguously and non-invasively to other sites in
the respiratory tract. Invasive pneumococcal disease (IPD) is deﬁned
as any condition in which SP is present in the blood, cerebrospinal
ﬂuid or other normally sterile body sites (W.H.O., 2003). Pneumococcaledicine, Public Health Section,
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. This is an open access article underpneumonia is associated with bacteremia in 10–30% of cases (W.H.O.,
2012a), in which case it is classiﬁed as invasive. There are two other
invasive forms of pneumococcal disease, i.e. septicemia and meningitis.
Septicemia is severe infection in the bloodstream, which can rapidly
become life-threatening. Patients are usually treated in intensive care
units, but septicemia is often fatal even with the most expensive treat-
ments. Survivors of severe sepsis are likely to have permanent organ
damage, cognitive impairments, and physical disabilities. The organisms
that cause bacterial meningitis differ somewhat by geographical region
and age, and they relate to different vaccination programs. In the USA,
where Haemophilus inﬂuenza vaccine was introduced in 1996, the
epidemiological features of bacterial meningitis have changed dramati-
cally in recent years, and nowadays its most common cause among
adults young and old is SP (Bhimraj, 2012).
Most of the burden of pneumococcal infections in adults relates to
pneumonia. Community-acquired pneumonia (CAP) is a respiratory
disease highly prevalent in the general population that has clinicallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
SP-related hospital admissions in the Veneto Region by patients' features (2008–2012).
Total Pneumonia Meningitis Septicemia
Total 23089 21848 225 1016
n (%) n (%) n (%) n (%)
Gender
Females 10748 (46.6) 10163 (46.5) 114 (50.7) 471 (46.4)
Males 12341 (53.4) 11685 (53.5) 111 (49.3) 545 (53.6)
Age group (years)
0–4 1776 (7.7) 1685 (7.7) 20 (8.9) 71 (7.0)
5–14 1223 (5.3) 1160 (5.3) 9 (4.0) 54 (5.3)
15–64 3490 (15.1) 3173 (14.5) 96 (42.7) 221 (21.8)
65–79 5491 (23.8) 5142 (23.5) 76 (33.8) 273 (26.9)
80+ 11109 (48.1) 10688 (48.9) 24 (10.7) 397 (39.1)
Nationality
Italian 22023 (95.4) 20856 (95.5) 208 (92.4) 959 (94.4)
Foreign 1066 (4.6) 992 (4.5) 17 (7.6) 57 (5.6)
Length of stay
0–7 7064 (30.6) 6743 (30.9) 48 (21.3) 273 (26.9)
8–15 10219 (44.3) 9787 (44.8) 64 (28.4) 368 (36.2)
16–30 4730 (20.5) 4381 (20.1) 83 (36.9) 266 (26.2)
N30 1076 (4.7) 937 (4.3) 30 (13.3) 109 (10.7)
Charlson comorbidity index
0 14130 (61.2) 13372 (61.2) 193 (85.8) 565 (55.6)
1 5482 (23.7) 5295 (24.2) 17 (7.6) 170 (16.7)
≥2 3477 (15.1) 3181 (14.6) 15 (6.7) 281 (27.7)
Comorbidities
Cerebrovascular
diseases
1434 (6.2) 1368 (6.3) 8 (3.6) 58 (5.7)
Heart diseases 1770 (7.7) 1697 (7.8) 6 (2.7) 67 (6.6)
Respiratory diseases 365 (1.6) 361 (1.7) 1 (0.4) 3 (0.3)
Diabetes mellitus 2140 (9.3) 2033 (9.3) 13 (5.8) 94 (9.3)
Cancer 1251 (5.4) 1063 (4.9) 10 (4.4) 178 (17.5)
Renal diseases 1545 (6.7) 1423 (6.5) 8 (3.6) 114 (11.2)
Died during hospital
stay
2542 (11.0) 2296 (10.5) 29 (12.9) 217 (21.4)
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2012). Themost common cause of CAP in adults in industrialized coun-
tries is SP, and this pathogen is identiﬁed in a signiﬁcant proportion of
patients hospitalized with CAP (Fine et al., 1996; Woo et al., 2001;
W.H.O., 2012b; Rodrigo et al., 2014). The methods used to identify a
pathogen responsible for pneumonia vary, depending on the equipment
available at a hospital's laboratory and on the design of studies on the
topic; and different pathogens are found in different seasons of the
year and geographical regions. Pneumococcal pneumonia has been
associatedwith amore severe clinical course, demandingmoremedical
resources than non-pneumococcal pneumonia (Pletz et al., 2012).
Pneumococcus is also an important cause of pneumonia in residents at
long-term care facilities (Loeb, 2014), and patients with pneumococcal
pneumonia are also more frequently admitted to hospital, especially if
they are elderly (Pletz et al., 2012; Bechini et al., 2014).
The aim of this work was to estimate the burden of hospitalization
for SP in the Veneto region by examining the SP-related hospital admis-
sions (SP-HA) to obtain epidemiological data and calculate the fatality
rate among these patients.
Material and methods
This was a retrospective study based on data collected from 2008
to 2012 in the National Surveillance System hospital database for the
Veneto Region (north-east Italy). This region has a total of 81 hospitals
and similar healthcare facilities, all of which were included in our anal-
ysis. In general, the ﬁrst-listed diagnosis concerns the main condition
identiﬁed during the patient's hospital stay, while other diagnoses
indicate associated or contributing conditions (comorbidities and/or
complications).
All hospital discharge records containing one of the following
codes in the International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation (ICD-9-CM) as a primary diagnosis were selected:
(i) pneumonia group: 481: “Pneumococcal pneumonia”; 485: “Broncho-
pneumonia, organism unspeciﬁed”; 486: “Pneumonia, organism un-
speciﬁed”, 482.30 “Pneumonia due to Streptococcus, unspeciﬁed”,
482.9 “Bacterial pneumonia, unspeciﬁed”; (ii)meningitis group: 320.1:
“Pneumococcal meningitis”; 322.9: “Meningitis of unspeciﬁed cause”;
and (iii) septicemia group: 038.2: “pneumococcal septicemia”; 038.9
“Unspeciﬁed septicemia”.
In the event of patients being readmitted to hospital within 30 days,
only their ﬁrst hospitalization was included in the analysis.
The proportion of SP-HA was calculated on the assumption that all
discharge records mentioning this pathogen were SP-HA, and that this
was also true for 36%, 58% and20%, respectively, of the cases of pneumo-
nia, meningitis and septicemia for which no pathogen was speciﬁed
(Welte et al., 2010; Thigpen et al., 2011; Rüggeberg et al., 2004; Pere
Domingo et al., 2013).
Age was categorized in ﬁve groups (0–4 years; 5–14 years, 15–64
years, 65–79 years and 80+ years). Length of stay (LOS) was deﬁned
as the time from admission to discharge from the hospital or
in-hospital death. Comorbidities were considered, based on the other
diagnostic codes recorded, identifying the followingmedical conditions:
diabetesmellitus (ICD9-CM code: 250), heart diseases (ICD9-CM codes:
410–414; 402.01, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91,404.93,
452, 428), cerebrovascular diseases (ICD9-CMcodes: 430–434, 436–438),
respiratory diseases (ICD-9-CMcodes: 491.1–491.8; 492–496),malignant
neoplasms (ICD-9-CM codes: 140–209), renal diseases (ICD-9-CM codes:
580–588, 591) and dementia (ICD-9-CM codes: 290, 331). Comorbidities
were also graded according to the Charlson Comorbidity Index (CCI)
(Charlson et al., 1987), calculated from the sum of the scores for the
severity of each comorbid condition, and then categorized as 0, 1, and
2 or more.
The cost to the health care system of the hospitalizations associated
with SP was calculated by considering the diagnostic cost groups and
the number of discharges. The diagnostic cost grouping is based ondiagnosis-related groups (DRG) of hospitalized patients according to
their ICD-9 code(s) at discharge, age, sex, and resource consumption.
The DRG calculations were completed using 3 M with Core Grouping
System Software.
The study was conducted on data routinely collected by the health
services and linked to anonymized records that make it impossible to
identify the individuals concerned. The data analysis was performed
on anonymized aggregated data. Data in the Local Health Authority
registries are recorded with the patient's consent and can be used as
aggregate data for scientiﬁc studies without further authorization
(Garante per la protezione dei dati personal, 2012). This study complies
with the Declaration of Helsinki and with Italian privacy law (Decree n.
196/2003 on the protection of personal data).
Statistical analysis
The SP-HA rates (by gender, age group, type of disease, and comor-
bidities) were obtained by dividing the estimated annual number of
hospitalizations for pneumonia by the annual population, according to
the ﬁgures supplied by the Veneto Region Statistics Ofﬁce, with the
rates expressed as hospitalizations per 100,000 population. The Veneto
population during the study period was stable, and the data analyzed
only concerned the resident population, excluding people living outside
the region.
The mean days of hospital stay and case-mortality rates (%) were
also calculated.
The data were analyzed using the chi square test and Student's t-test
for unpaired data, as appropriate. A p value b0.05was considered signif-
icant. The analyses were performed using the Statistical Package for the
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over the years considered were assessed in terms of average annual
percent changes (AAPC), a summary measure of the trend over a given
ﬁxed interval. It is computed as a weighted average of the annual per-
cent change (APC) emerging from the join-point model, using weights
equating to the length of the APC interval. If an AAPC lies entirely within
a single join-point segment, the AAPC is the same as the APC for that
segment (Boehmer et al., 2011).Results
We identiﬁed 62,946 hospital discharge records concerning diseases
potentially associated with SP between January 1, 2008 and December
31, 2012; and 935 (1.5%) were readmissions within 30 days. A speciﬁc
diagnosis of SP-related disease was mentioned in 2.9%, 6.5% and
58.0% of patients admitted for pneumonia, septicemia and meningitis,
respectively.
The proportion of SP-HAwas estimated at 23,089 of all the discharge
records selected (37.2%) and 21,848 (94.6%) were coded as cases of
pneumonia, 1016 (4.4%) as septicemia, and 225 (1.0%) as meningitis.
Overall, the highest proportion of hospitalizations involved elderly
patients N65 years old (71.9%). Among all the discharge records with a
SP-related diagnosis, 36.2% concerned patients with at least one comor-
bidity. The characteristics of the sample are shown in Table 1.
For the sample of SP-HA as a whole, the length of stay (LOS) was a
mean 11.6 ± 10.2 days, and it was signiﬁcantly higher in females
(11.8 ± 10.1 vs 11.5 ± 10.3 in males p b 0.01). Divided by diagnostic
group, the mean hospital stay was 14.2 ± 13.0, 16.9 ± 16.2 and
11.4 ± 9.1 for septicemia, meningitis and pneumonia, respectively.
Patients who had comorbidities had a longer mean hospital stay than
those who did not (CCI = 2+ LOS: 14.0 days; CCI = 1, LOS 13.4 days;
CCI = 0, LOS 10.3 days; CCI = 0 versus both other groups p b 0.05).
The number of chronic comorbidities generally rose with age. Their
frequency and case fatality rate by type is shown in Fig. 1.
During the period considered, the estimated SP-HA rate was 94.0/
100,000 population (89.0, 0.9 and 4.1 per 100,000 for pneumonia,
meningitis and septicemia, respectively). Fig. 2 shows the trend of the
hospitalization rates year by year, by studied group.
The estimated hospitalization rates suggest a greater burden of dis-
ease for males (102.8/100,000 as opposed to 85.6/100,000 females;
p b 0.01) with no signiﬁcant changes seen over the years considered
(females AAPC: −0.0, CI 95%: −1.5; 1.5; males AAPC: −0.4 CI 95%:
−2.2;1.3). In both genders, the SP-HA rate showed two age peaks,
one in children and the other in elderly adults (Fig. 3).Fig. 1. Percentages of chronic comorbidities (bars) and case fatality rate (lines) of SP-related hoThe overall expenditure for SP-HA during the period of observation
was around €14.8 million a year, with an average cost of €3120 per pa-
tient (€2927 for cases of pneumonia, €8239 for meningitis, and €5520
for septicemia).
Discussion
The present study estimated the trends of the hospital admission
rates for SP-related invasive disease in a cohort of 5 million citizens,
and the results indicate that the heavy burden of these conditions on
hospital resources is an important public health issue.
It is not easy to estimate themorbidity of invasive SP-relateddiseases
in the general population. This is partly because the currently-available
epidemiological picture is still hazy due to differences in study designs
and population proﬁles, in access to health care and recording methods,
but hospital discharge data can prove useful for assessing the cases
severe enough to warrant hospitalization (Boehmer et al., 2011).
The overall estimated SP-HA rate was 94.0/100,000 population
during the years 2008–2012, and it was 1.2 times higher for males
than for females. The age groups considered in our sample also revealed
differences in the hospitalization rates, with children and older people
being more affected in all the diagnostic groups considered.
One of the difﬁculties encountered in studies in this setting concerns
the limited availability of microbiological data and the dubious reliabil-
ity of the ﬁgure identiﬁed for all SP-HA due to coding errors in hospital
discharge records. In our data set, there were very few diagnoses spec-
ifying that SP was involved, and the ﬁgures varied by type of disease —
low for pneumonia and high for meningitis (2.9% vs 58%). A recent re-
view analyzing the burden of CAP among adults in Europe reported
that Italy had the lowest pneumococcus identiﬁcation rate, and recom-
mended that diagnostic assays be improved to detect pneumococcal
pneumoniamore effectively and thus provide amore accurate epidemi-
ological picture (Welte et al., 2010).
Using hospital discharges records makes it difﬁcult to distinguish
community-acquired infections, but our analyses were conducted on
the ﬁrst diagnosis prompting admission to hospital, so our cases are
unlikely to have included hospital-acquired infections.
Despite the relatively short period considered, our data indicated a
higher SP-HA rate among elderly people, and particularly among those
with comorbidities. Our ﬁgures also showed a slight (but not statistical-
ly signiﬁcant) downward trend in the Veneto's SP-HA rate.
The rate of SP-HA found associated with pneumonia (89.0/100,000
population) is bound to underestimate the true burden of this disease
in the region considered because most patients with pneumonia are
not hospitalized. Our ﬁgure probably only concerns the more severespital admissions according to age group and type of comorbidity (2008–2012).
Fig. 2. Annual SP-related hospital admissions per 100,000 population in the Veneto Region, by type of disease (2008–2012).
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patients require admission to hospital (Guest and Morris, 1997).
A recent paper indicated that the overall pneumonia hospitalization
rate in the Veneto region had increased slightly, but dropped signiﬁ-
cantly among infants aged 0–4 years. This could be thanks to a greater
PCV vaccination coverage in this age group since 2008 (Baldo et al.,
2014). The same trend has been seen in other regions too (Durando
et al., 2009; Martinelli et al., 2014).
The incidence of sepsis has recently increased in industrialized coun-
tries, and it is an important cause of death. It is commonly caused by
Gram-positive bacterial and fungal organisms (Martin et al., 2003;
Alberti et al., 2003). Meanwhile, the rate of bacterial meningitis has
been declining, although the disease is still often fatal. Patients with
meningitis are more likely to be older adults (Thigpen et al., 2011).
An important aspect of this trend relates to the vaccine-preventable
bacterial diseases in areas where vaccine coverage is high, so the use
of effective vaccines can be expected to have a substantial impact on
these infectious diseases. The beneﬁts have been most notable in chil-
dren with the advent of effective conjugate vaccines since the 1990s
(Martin et al., 2014). Our data conﬁrm that the elderly and children are
at much higher risk of developing meningitis and sepsis than younger
adults.Fig. 3. SP-HA rates (×100,000 population) in the Veneto RegioRegarding outcome, the overall fatality rate for patients involved in
SP-HA was 10.4% and, divided by disease group, it was 21.5%, 10.5%
and 9.9% for septicemia, meningitis and pneumonia, respectively. The
worldwide morbidity and mortality rates associated with pneumococ-
cal pneumonia are still high, with the mortality rate ranging from 6.4%
to N40% in different outpatient, inpatient and intensive-care patient set-
tings (Carr et al., 1991). There are clearly many factors that can contrib-
ute to mortality among patients requiring hospitalization, which can be
grouped into patient-related factors, care process factors, physician-
related factors, and others. In our analysis, the factors associated with
a higher mortality risk among hospitalized cases were older age, male
gender, and a higher score on the Charlson Co-morbidity Index. Many
studies have conﬁrmed that age and comorbidities are predictors of
outcome (Thomas and Wu, 2005; Martin et al., 2006).
The economic burden of pneumonia for the health system depends
on a patient's age, children and the elderly having the highest incidence
of SP-HA and incurring the greatest economic burden. Themean hospital
stay and the in-hospital mortality rates were found higher for patients
with comorbidities, suggesting a more severe disease on admission.
Our study shows that SP-HAhas a considerable impact on the health
services in the Veneto region. Vaccination strategies can be used for
the primary prevention of the infection, and could reduce the burdenn by gender, type of disease, and age group (2008–2012).
31V. Baldo et al. / Preventive Medicine Reports 2 (2015) 27–31of SP-related disease. Prevention remains the most valuable tool in
efforts to contain the phenomenon. The development of pneumococcal
conjugate vaccines has had a signiﬁcant impact on the burden of the
related diseases in countries where they have been introduced (Albrich
et al., 2007). Vaccination can naturally only protect against CAP, not
hospital-acquired pneumonia, which is caused by different types of
pathogens (Micek et al., 2011).
Conclusion
Our study shows that hospitalizations for patients with conditions
caused by S. pneumoniae have a considerable impact on the health
services, especially when children and the elderly are involved. Judging
from our hospital discharge records, it would seem important to
conduct prospective epidemiological studies with the cooperation of
specialists in this ﬁeld, with a view to obtaining a more precise picture
of the epidemiological situation regarding these diseases.
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